News
Multimedia
Publication
Conferences
Resources
Subscribe
Webcasts

Spotlight -

Downstream Processing|

Upstream Processing

|Articles|July 1, 2015

Cell Therapies

Eric Langer, Managing partner at BioPlan Associates, speaks with BioPharm International about emerging trends in cell therapy.

Eric Langer, Managing Partner at BioPlan Associates, spoke with BioPharm International about emerging trends in cell therapy.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Content

idea, light bulb, rocket, innovation, technology, business, development, imagination, inspiration, intelligence, hand hold light bulb to light up solution and advertise hit the goal and target rocket. | Image credit: © Garun Studios - stock.adobe.com

New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy

ByFeliza Mirasol

January 22nd 2026

Single helix RNA, Epigenetics concept | Image credit: © Artur - © Artur - stock.adobe.com

European Approval of Donidalorsen Expands RNA-Targeted Prevention Strategies for HAE

ByFeliza Mirasol

January 21st 2026

Bispecific antibody colored heavy chain in green and pink, light chain blue and yellow against gray background; glycosylated bispecific immunoglobulin engineered to target different antigens 3d render | Image credit: © huenstructurebio.com - © huenstructurebio.com - stock.adobe.com

Next-Generation Modalities Drive New Antibody Discovery

ByFeliza Mirasol

January 21st 2026

Allergist doctor injects against allergies to a young girl, a medical. Allergen-specific immunotherapy, copy space | Image credit: © HENADZY - © HENADZY - stock.adobe.com

GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies

ByFeliza Mirasol

January 20th 2026

Sad blue-grey eyes of elderly woman looking to the side, extreme close-up shot | Image credit: © pressmaster - © pressmaster - stock.adobe.com

EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy

ByFeliza Mirasol

January 19th 2026

Trending on BioPharm International

Next-Generation Modalities Drive New Antibody Discovery

New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy

European Approval of Donidalorsen Expands RNA-Targeted Prevention Strategies for HAE

GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies

State of the Bio/Pharma Workforce: A Comparative Analysis of Employment Trends and Industry Sentiment